LoginSignup
TRD

Entrada

Stock
Stock
ISIN: US29384C1080
Ticker: TRDA
US29384C1080
TRDA

Price

Price

Frequently asked questions

What is Entrada's market capitalization?

The market capitalization of Entrada is $675.43M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.

What is Entrada's Price-to-Earnings (P/E) ratio?

The Price-to-Earnings (P/E) ratio (TTM) for Entrada is 11.32. This ratio helps investors assess whether a stock is overvalued or undervalued compared to its earnings.

What is the Earnings Per Share (EPS) for Entrada?

Entrada's Earnings Per Share (EPS) over the trailing twelve months (TTM) is $1.594. EPS indicates the company's profitability on a per-share basis.

What are the analyst ratings and target price for Entrada's stock?

Currently, 4 analysts cover Entrada's stock, with a consensus target price of $22.50. Analyst ratings provide insights into the stock's expected performance.

What is Entrada's revenue over the trailing twelve months?

Over the trailing twelve months, Entrada reported a revenue of $215.23M.

What is the EBITDA for Entrada?

Entrada's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $61.30M. EBITDA measures the company's overall financial performance.

What is the free cash flow of Entrada?

Entrada has a free cash flow of -$17.46M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.

How many employees does Entrada have, and what sector and industry does it belong to?

Entrada employs approximately 177 people. It operates in the Health Care sector, specifically within the Biotechnology & Drugs industry.

What is the free float of Entrada's shares?

The free float of Entrada is 31.86M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap

 $675.43M

EPS (TTM)

 $1.594

Free Float

 31.86M

P/E ratio (TTM)

 11.32

Revenue (TTM)

 $215.23M

EBITDA (TTM)

 $61.30M

Free Cashflow (TTM)

 -$17.46M

Pricing

52W span
$10.95$20.49

Analyst Ratings

The price target is $22.50 and the stock is covered by 4 analysts.

Buy

4

Hold

0

Sell

0

Information

Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a class of medicines, which engages intracellular targets that have long been considered inaccessible. The Company’s Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Through its proprietary, highly versatile and modular EEV platform (EEV Platform), the Company is building a robust development portfolio of therapeutic candidates. Its first two drug candidates, ENTR-601-44 and VX-670, are in clinical trials. VX-670 for dystrophy type 1 (DM1) is designed to block the triplet repeats in the messenger RNA (mRNA). ENTR-601-44 is in a Phase I clinical trial. The Company also announced the selection of additional clinical candidates within its Duchenne franchise, ENTR-601-45 and ENTR-601-50.

177

Biotechnology & Drugs

Health Care

Identifier

ISIN

US29384C1080

Primary Ticker

TRDA
Join the conversation
Sign upLogin